Kanada - anglų - Health Canada

pharmascience inc - tamoxifen (tamoxifen citrate) - tablet - 20mg - tamoxifen (tamoxifen citrate) 20mg - antineoplastic agents

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bryant ranch prepack - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 20 mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; colloidal anhydrous silica; maize starch; magnesium stearate; purified water - palliative treatment of breast cancer.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; lactose monohydrate; maize starch; purified water; colloidal anhydrous silica - palliative treatment of breast cancer.

Malta - anglų - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - tamoxifen - film-coated tablet - tamoxifen 20 mg - endocrine therapy

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

american health packaging - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 10 mg

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 10mg

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 10 mg

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

fortovia therapeutics inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen 20 mg in 10 ml - soltamox is indicated for the treatment of adult patients with estrogen receptor-positive metastatic breast cancer. soltamox is indicated: - for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer - to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer. in adult women with dcis, following breast surgery and radiation, soltamox is indicated to reduce the risk of invasive breast cancer [see boxed warning and clinical studies (14.3)] . soltamox is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer.[see boxed warning and clinical studies (14.4)] . - soltamox is contraindicated in patients with known hypersensitivity (e.g., angioedema, serious skin reactions) to tamoxifen or any other soltamox ingredient [see adverse reactions (6.2)] . - soltamox is contraindicated in patients who require concomitant warfarin therapy or have a history of d

Australija - anglų - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - tamoxifen citrate, quantity: 15.2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; gelatin; hypromellose; macrogol 300; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide - treatment of breast cancer nolvadex is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).